Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...7879808182838485868788...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal, Monotherapy:  Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations. (Pubmed Central) -  Jul 4, 2020   
    Due to the diversity of adaptive responses to monotherapy, monitoring the response to treatment in patients is critical to understand the path that leads to resistance and to guide the optimal therapeutic drug combinations in the clinical setting. We envisage that applying such a rationale-based therapeutic strategy will improve treatment efficacy in HNC patients.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Clinical, Journal:  Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02). (Pubmed Central) -  Jul 4, 2020   
    P2
    This prospective biomarker design study has important clinical implications because many prospective clinical trials are designed with the hypothesis that BRAF mutation per se and MEK and PIK3CA downstream pathways are critical for colorectal tumor survival. The results lead to the question of whether these pathways should be considered as passengers instead of drivers.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Review, Journal:  Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC). (Pubmed Central) -  Jul 3, 2020   
    In so far as the clinical data of tumor sidedness is concerned, very few reviews have discussed the clinical implications of sidedness in heavily pre-treated metastatic colorectal cancer (second and subsequent lines of therapy in metastatic disease). This review aims to fill the current gap in this setting.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Journal:  Zr-immuno-PET: towards a non-invasive clinical tool to measure target engagement of therapeutic antibodies in-vivo. (Pubmed Central) -  Jul 2, 2020   
    These results form a crucial base for measurement of target-engagement by therapeutic antibodies in-vivo with Zr-immuno-PET. For future studies, a pilot phase including at least 3 scans ≥ 1 day p.i., is required to assess non-specific uptake as a function of time, to optimize study design for detection of target engagement.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. (Pubmed Central) -  Jul 1, 2020   
    Other alterations, such as EGFR T790 M, are responsive to osimertinib, while the EGFR C797S alteration seen in osimertinib resistance demonstrates preclinical sensitivity to combined brigatinib and cetuximab. These observations indicate that clinical resistance can be overcome by utilizing advanced genomic interrogation coupled with computer modeling.
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date, Combination therapy:  Bevacizumab in Multiple Phase I Combinations (clinicaltrials.gov) -  Jun 30, 2020   
    P1,  N=343, Completed, 
    These observations indicate that clinical resistance can be overcome by utilizing advanced genomic interrogation coupled with computer modeling. Active, not recruiting --> Completed | Trial completion date: Oct 2020 --> Apr 2020 | Trial primary completion date: Oct 2020 --> Apr 2020
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Red Meat Allergies after Lone Star Tick (Amblyomma americanum) Bites. (Pubmed Central) -  Jun 28, 2020   
    Following confirmation by challenge testing, patients with red meat allergies should avoid red meats, foods containing gelatin, and intravenous immunotherapy with monoclonal antibodies such as cetuximab and infliximab produced in SP2/0 mouse cell lines. Red meat allergy after tick bites represents an emerging threat from tick bites in addition to infectious diseases.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Boosting of the enhanced permeability and retention effect with nanocapsules improves the therapeutic effects of cetuximab. (Pubmed Central) -  Jun 27, 2020   
    The nanocapsule-based delivery system efficiently delivered tAbs to tumor tissues and released them to boost the EPR effect, which facilitated further tumor accumulation of the tAbs. This novel self-augmentation of the EPR effect facilitated by the biological characteristics of tAbs and nanotechnology contributed to the improvement of the therapeutic effect of tAbs, and stimulated new ideas for antibody-based tumor therapy.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
    Enrollment open, Surgery:  SULTAN: Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (clinicaltrials.gov) -  Jun 25, 2020   
    P2,  N=140, Recruiting, 
    Acquired resistance, in patients with initial treatment benefit, is mainly explained by polyclonal emergence of RAS, BRAF and EGFR mutations in ctDNA. Suspended --> Recruiting
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    [VIRTUAL] Mammalian Meat Allergy – A Novel Presentation and a Review of the Literature () -  Jun 20, 2020 - Abstract #AADVMX2020AAD-VMX_184;    
    Severe anaphylaxis has also been seen following cetuximab treatment, as α-gal residues are present on the Fab segments of the monoclonal antibody...To our knowledge, this is the first reported case of MMA presenting as exfoliative erythroderma. We review the relevant literature and the postulated pathogenesis behind this presentation.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal, Combination therapy:  Monomer preference of EGFR tyrosine kinase inhibitors influences the synergistic efficacy of combination therapy with cetuximab. (Pubmed Central) -  Jun 19, 2020   
    In this study, we evaluated the effects of multiple EGFR-TKIs on the EGFR monomer-dimer equilibrium by inducing dimerization-impairing mutations in cells expressing EGFR Interestingly, we found that afatinib and dacomitinib exhibit a monomer preference: cells expressing dimerization-impaired EGFR mutants exhibited increased sensitivity to afatinib and dacomitinib relative to those with dimerization-competent EGFR mutants...In addition, we propose the novel concept that monomer-dimer equilibrium is an important factor in determining EGFR-TKI efficacy. These findings provide novel insights into treatment strategies for EGFR-TKI-refractory non-small cell lung cancer.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Metallopeptidase Inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer. (Pubmed Central) -  Jun 19, 2020   
    Different types of treatment are available for patients with advanced metastatic colorectal cancer, including targeted biological agents, such as cetuximab, a monoclonal antibody that targets EGFR...In addition, TIMP-1 inhibited c-Kit shedding in CRC cells grown in the presence of exogenous TIMP-1. Given the regulatory roles that c-Kit plays in cell proliferation and migration, and the realization that c-Kit is an important oncogene in CRC, it is likely that some of the biological effects of TIMP-1 overexpression in CRC may be exerted through its effect on c-Kit signaling.
  • ||||||||||  ficlatuzumab (AV-299) / AVEO, Biodesix, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    P1 data, Journal:  Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. (Pubmed Central) -  Jun 19, 2020   
    An increase in peripheral T cells, particularly the CD8 subset, was associated with treatment response whereas progression was associated with expansion of a distinct myeloid population. This well-tolerated combination demonstrated promising activity in cetuximab-resistant, advanced HNSCC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal, IO Biomarker:  Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma. (Pubmed Central) -  Jun 18, 2020   
    Recruiting --> Active, not recruiting | Trial completion date: Oct 2030 --> Dec 2029 | Trial primary completion date: Mar 2021 --> Dec 2019 Altogether, these results suggest that IL-1α in combination with cetuximab can induce a T cell-dependent anti-tumor immune response and may represent a novel immunotherapeutic strategy for EGFR-positive HNSCCs.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, irinotecan / Generic mfg.
    Review, Journal:  Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. (Pubmed Central) -  Jun 18, 2020   
    Our working hypothesis suggests that the CALGB/SWOG 80405 and FIRE-3 studies are complementary rather than discrepant, and it provides an explanation for their opposing interpretations. In conclusion, proper interpretation of the CALGB/SWOG 80405 and FIRE-3 results requires an in-depth examination of the complex interplay, not only between the targeted biological agents and chemotherapeutic drugs, but also between therapies and the tumour biology and microenvironment, for each line of treatment.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Palbociclib: a new partner for cetuximab? (Pubmed Central) -  Jun 18, 2020   
    In conclusion, proper interpretation of the CALGB/SWOG 80405 and FIRE-3 results requires an in-depth examination of the complex interplay, not only between the targeted biological agents and chemotherapeutic drugs, but also between therapies and the tumour biology and microenvironment, for each line of treatment. No abstract available
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  Cetuximab Rechallenge Study (clinicaltrials.gov) -  Jun 18, 2020   
    P2,  N=17, Completed, 
    No abstract available Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Apr 2020 | Trial primary completion date: Dec 2021 --> Apr 2020
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, paclitaxel / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Clinical, Journal:  A large single hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents. (Pubmed Central) -  Jun 15, 2020   
    P2YRs mediate HNSCC cell responses to extracellular nucleotides and genetic or pharmacological blockade of P2YR signaling attenuates tumor cell proliferation and tumorigenesis, suggesting that the P2YR represents a novel therapeutic target in HNSCC. This experience allows us to describe general management plans, as well as specific patient phenotypic patterns, predictors for reactions and risk considerations which need a tailored approach (taking into account the three prominent drug categories: platins, taxanes and biologicals).
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Primary Tumor Resection for Stage IV Colorectal Cancer in the Era of Targeted Chemotherapy. (Pubmed Central) -  Jun 15, 2020   
    This experience allows us to describe general management plans, as well as specific patient phenotypic patterns, predictors for reactions and risk considerations which need a tailored approach (taking into account the three prominent drug categories: platins, taxanes and biologicals). All three analyses revealed that, in the current era of chemotherapy with target agents, primary tumor resection was only marginally influential and did not significantly improve overall survival over chemotherapy alone.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Preclinical, Journal:  Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. (Pubmed Central) -  Jun 14, 2020   
    Taken together, in our current study we have developed a PEGylated targeted nanoconjugate ACG44P1000 that showed enhanced selectivity towards pancreatic cancer cells and pancreatic stellate cells, among others, for gemcitabine delivery. We will investigate the ability of these optimized conjugates to inhibit desmoplasia and tumor growth in vivo in our future studies.
  • ||||||||||  cisplatin / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  Recurrent cisplatin hypersensitivity reaction after first exposure: A case report. (Pubmed Central) -  Jun 12, 2020   
    Skin allergy testing has limited sensitivity for platinum-based chemotherapy and caution should be exercised in weighing risk and benefits of re-exposure. Although rare, cisplatin hypersensitivity can present after first exposure.